Skip to main content

Table 2 NT-proBNP and BNP measurements

From: Brain natriuretic peptide for prediction of mortality in patients with sepsis: a systematic review and meta-analysis

Marker

Study

Assay†

Optimal Timing

Cut-off Point

(pg/ml)

Sensitivity/Specificity

AUC¶

Proportion of Elevated BNPs (%)

NT-proBNP

Varpula 2007 [28]

Roche, Elecsys 2010 analyzer

On admission

7090

58/66

0.631

40.6

 

Mokart 2007 [29]

Roche, Elecsys 2010 analyzer

Day 2 after admission

6624

86/77

0.87

54.9

 

Roch 2005 [31]

Roche, Elecsys 2010 analyzer

Within 24 hours after admission

13600

73/83

0.8

48.7

 

Brueckmann 2005 [32]

Enzyme immunoassay (Biozol)

Day 2 after admission

11900

50/90

0.68

21.1

 

Sturgess 2010b* [23]

Roche, Elecsys 2010 analyzer

Within 72 hours after admission

400

83/40

0.67

66.7

BNP

Perman 2011 [22]

Biosite Diagnostics, Triage

On admission

49

63/69

0.69

47.6

 

Zhao 2009 [24]

Immunofluorescence assay‡

24 hours after admission

681.4

91.4/80.3

0.915

47.1

 

Chen 2009 [25]

Biosite Diagnostics, Triage

Within 24 hours after admission

113

86/55

0.737

32.1

 

Yucel 2008 [26]

Immunoradiometric assay, Shionoria

On admission

32.1

100/95

0.99

52.5

 

Post 2008 [27]

Biosite Diagnostics, Triage

Day 5 after admission

121

76.3/52.7

0.648

59.1

 

Ueda 2006 [30]

Immunoradiometric assay, Shionoria

Day 2 after admission

650

92/80

0.85

59.1

 

Charpentier 2004 [33]

Immunoradiometric assay, Shionoria

Day 2 after admission

190

70/67

0.66

44.1

 

Sturgess 2010a* [23]

Biosite Diagnostics, Triage

Within 72 hours after admission

254

83/60

0.76

52.4

  1. BNP = brain natriuretic peptide, NT-proBNP = N-terminal pro-B-type natriuretic peptide. *The study reported both BNP (Sturgess 2010a) and NT-proBNP (Sturgess 2010b). †Manufacture and kind of assay. ‡The manufacture was not reported. ¶ AUC indicates the area under the receiver operating characteristic curve.